AU2017263454B2 - Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors - Google Patents

Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors Download PDF

Info

Publication number
AU2017263454B2
AU2017263454B2 AU2017263454A AU2017263454A AU2017263454B2 AU 2017263454 B2 AU2017263454 B2 AU 2017263454B2 AU 2017263454 A AU2017263454 A AU 2017263454A AU 2017263454 A AU2017263454 A AU 2017263454A AU 2017263454 B2 AU2017263454 B2 AU 2017263454B2
Authority
AU
Australia
Prior art keywords
gly
ala
glu
arg
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017263454A
Other languages
English (en)
Other versions
AU2017263454A1 (en
Inventor
Neeraj Jagdish Agrawal
Kristine M. DARIS
Dina A. FOMINA YADLIN
Randal R. Ketchem
Jeffrey T. Mcgrew
Trent P. MUNRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2017263454A1 publication Critical patent/AU2017263454A1/en
Priority to AU2023200660A priority Critical patent/AU2023200660B2/en
Application granted granted Critical
Publication of AU2017263454B2 publication Critical patent/AU2017263454B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017263454A 2016-05-11 2017-05-11 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors Active AU2017263454B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200660A AU2023200660B2 (en) 2016-05-11 2023-02-08 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662334966P 2016-05-11 2016-05-11
US62/334,966 2016-05-11
PCT/US2017/032139 WO2017197098A1 (en) 2016-05-11 2017-05-11 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200660A Division AU2023200660B2 (en) 2016-05-11 2023-02-08 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

Publications (2)

Publication Number Publication Date
AU2017263454A1 AU2017263454A1 (en) 2018-12-06
AU2017263454B2 true AU2017263454B2 (en) 2023-02-09

Family

ID=58873869

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017263454A Active AU2017263454B2 (en) 2016-05-11 2017-05-11 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
AU2023200660A Active AU2023200660B2 (en) 2016-05-11 2023-02-08 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200660A Active AU2023200660B2 (en) 2016-05-11 2023-02-08 Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors

Country Status (17)

Country Link
US (2) US11384140B2 (enExample)
EP (2) EP3455359B1 (enExample)
JP (2) JP6972022B2 (enExample)
KR (2) KR102323519B1 (enExample)
CN (2) CN115873904A (enExample)
AU (2) AU2017263454B2 (enExample)
BR (1) BR112018073316A2 (enExample)
CA (1) CA3024027A1 (enExample)
CL (1) CL2018003210A1 (enExample)
EA (1) EA201892588A1 (enExample)
ES (1) ES2914118T3 (enExample)
IL (2) IL300591A (enExample)
MA (1) MA44976A (enExample)
MX (2) MX394682B (enExample)
SG (1) SG11201810040WA (enExample)
TW (2) TWI757291B (enExample)
WO (1) WO2017197098A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093331A1 (en) * 2016-11-16 2018-05-24 Agency For Science, Technology And Research Attenuated glutamine synthetase as a selection marker
BR112019024750A2 (pt) 2017-05-24 2020-06-09 Thoeris Gmbh uso de glutamina sintetase no tratamento da hiperamonemia
CN109988777A (zh) * 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
SG11202109642SA (en) * 2019-05-07 2021-10-28 Amgen Inc Vectors and expression systems for producing recombinant proteins
WO2023011442A1 (en) * 2021-08-03 2023-02-09 Shanghai Zhenge Biotechnology Co., Ltd. Selectable markers for eukaryotic expression system
CN118804978A (zh) * 2021-12-27 2024-10-18 上海臻格生物技术有限公司 用于重组生产系统的新型标志物
EP4496884A1 (en) * 2022-03-23 2025-01-29 Boehringer Ingelheim International Gmbh New glutamine synthetase variants as selection marker
AU2023238775A1 (en) 2022-03-23 2024-10-31 Boehringer Ingelheim International Gmbh Bacterial glutamine synthetase as selection marker in mammalian cells
WO2025037708A1 (en) * 2023-08-16 2025-02-20 Korea Advanced Institute Of Science And Technology Method for selection of cell line expressing high levels of recombinant protein using glutamine synthetase split expression vector
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
CN118006685B (zh) * 2024-04-07 2024-07-23 上海碧博生物医药科技有限公司 一种快速的高表达单克隆细胞株构建方法
WO2025250814A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Intein based split glutamine synthetase engineering

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0819508B2 (ja) 1987-08-19 1996-02-28 三菱マテリアル株式会社 Ｆｅ−Ｃｏ基合金製高周波用磁芯材
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5624818A (en) 1991-09-09 1997-04-29 Fred Hutchinson Cancer Research Center Nucleic acids encoding regulatory proteins that dimerize with Mad or Max
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
CA2222914C (en) 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DK1196566T3 (da) * 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
PT1434871T (pt) * 2001-09-20 2017-04-05 Immunex Corp Seleção de células que expressam polipéptidos heteroméricos
GB0200977D0 (en) * 2002-01-17 2002-03-06 Lonza Biologics Plc Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
WO2004038003A2 (en) * 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US7674618B2 (en) * 2003-09-04 2010-03-09 Medarex, Inc. Expression vector
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012027533A1 (en) * 2010-08-25 2012-03-01 Gt Life Sciences, Inc. Selectable markers and related methods
US20130244231A1 (en) * 2010-11-08 2013-09-19 Jcr Pharmaceuticals Co., Ltd. Novel expression vector
WO2012095514A1 (en) * 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
AU2012203048A1 (en) * 2011-05-24 2012-12-13 Agency For Science, Technology And Research IRES mediated multicistronic vectors
KR101411740B1 (ko) * 2012-05-29 2014-06-27 한화케미칼 주식회사 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants

Also Published As

Publication number Publication date
CN109219660A (zh) 2019-01-15
TW202223093A (zh) 2022-06-16
KR102439719B1 (ko) 2022-09-02
EP4067493A1 (en) 2022-10-05
JP2019514417A (ja) 2019-06-06
JP6972022B2 (ja) 2021-11-24
MA44976A (fr) 2019-03-20
KR20190005193A (ko) 2019-01-15
CN115873904A (zh) 2023-03-31
AU2023200660B2 (en) 2024-12-12
US20230048658A1 (en) 2023-02-16
JP2022033734A (ja) 2022-03-02
US11384140B2 (en) 2022-07-12
IL262923B1 (en) 2023-04-01
CA3024027A1 (en) 2017-11-16
SG11201810040WA (en) 2018-12-28
AU2017263454A1 (en) 2018-12-06
WO2017197098A1 (en) 2017-11-16
TW201805422A (zh) 2018-02-16
IL262923B2 (en) 2023-08-01
BR112018073316A2 (pt) 2019-06-04
EA201892588A1 (ru) 2019-06-28
CL2018003210A1 (es) 2019-02-15
MX2018013882A (es) 2019-03-14
CN109219660B (zh) 2023-01-06
AU2023200660A1 (en) 2023-03-09
EP3455359B1 (en) 2022-03-09
US20190127452A1 (en) 2019-05-02
IL262923A (en) 2019-01-31
IL300591A (en) 2023-04-01
MX2022009674A (es) 2022-09-09
KR102323519B1 (ko) 2021-11-09
TWI821905B (zh) 2023-11-11
MX394682B (es) 2025-03-24
JP7344949B2 (ja) 2023-09-14
EP3455359A1 (en) 2019-03-20
TWI757291B (zh) 2022-03-11
ES2914118T3 (es) 2022-06-07
KR20210135635A (ko) 2021-11-15

Similar Documents

Publication Publication Date Title
AU2023200660B2 (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
JP6797950B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現
HK40082650A (en) Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
US20220243222A1 (en) Vectors and expression systems for producing recombinant proteins
EA043386B1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
TW202328442A (zh) 平臺宿主對ｉｇｆ—培養基之適應
HK40070504A (en) Methods of cell selection
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
HK1231928A1 (en) Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
HK1231928B (zh) 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)